Cleanhill Partners Announces Partnership with CleanJoule to Drive Growth of Sustainable Aviation Fuel
1.11.2021 17:00:00 EET | Business Wire | Press release
Cleanhill Partners, a private equity firm pursuing investments in the energy transition sector that contribute to decarbonization, announced a partnership with CleanJoule LLC, the world’s leading producer of full-performance sustainable aviation fuels (SAF). The deal provides CleanJoule with the financial, strategic and operational resources to accelerate the commercialization of its technology – advancing meaningful efforts to slow climate change and addressing energy shortages predicted to disrupt the aviation industry within the next 30 years. The investment comes on the heels of Cleanhill’s partnership with KORE Power, Inc., the leading U.S.-based developer of battery cell technology for the electric transportation and energy storage industries.
“As decarbonization of the aviation sector continues to present a daunting technological challenge and mounting environmental imperative, we are thrilled to be able to partner with Cleanhill and advance our shared vision of creating cost-effective clean energy solutions that can be deployed today,” said Dr. Mukund Karanjikar, CEO of CleanJoule. “Having led the way in developing the industry’s most eco-friendly and commercially viable sustainable aviation fuel, CleanJoule is now very well-positioned to significantly expand its adoption and shorten the timeframes to achieving a greener global aviation industry.”
Dr. Karanjikar, who previously held innovation-focused roles at Technology Holding LLC and Chevron, has spent more than a decade developing the CleanJoule SAF technology, along with Dr. Ashok Joshi, a globally recognized, high-technology entrepreneur. Validated by the U.S. Department of Defense and U.S. Department of Energy, CleanJoule’s proprietary production process converts biomass into a superior SAF molecule along with a bio-derived rubber co-product, yielding the only carbon negative, zero-petroleum, full performance and 100 percent drop-in SAF that can be used in a variety of commercial aviation engines without modification.
Cleanhill co-founders and Managing Partners Ash Upadhyaya and Rakesh Wilson will join CleanJoule’s board of directors. Having previously served in leadership positions at KKR and Apollo, respectively, they bring decades of experience investing across the energy value chain.
“Cleanhill is laser-focused on partnering with companies such as CleanJoule that are solving large-scale decarbonization challenges with timely, commercially viable approaches,” said Upadhyaya and Wilson. “By rapidly scaling CleanJoule in collaboration with our industry partners, we’ll be advancing efforts of vital importance to the climate and global economy.”
Kirkland & Ellis LLP served as legal counsel to Cleanhill Partners.
About CleanJoule
CleanJoule is the world’s leading innovator of full-performance SAF, founded by a passionate and creative group of engineers, scientists and visionaries focused on aviation fuels, with the purpose of creating a sustainable planet, reducing global carbon emissions and ultimately combatting climate change. CleanJoule’s highly innovative technology allows it to harness existing energy from biomass and convert it to superior performance aviation fuel as well as bio-rubber that can be used in various consumer and commercial products. For more information, visit www.cleanjoule.com .
About Cleanhill Partners
Cleanhill Partners is a private equity firm pursuing investments in the energy transition sector that contribute to decarbonization. The firm invests in scalable businesses with visibility into revenues, earnings and cash flow growth, leveraging its thesis-driven approach and operational expertise to enhance value in each of our investments. The firm has offices in New York and Houston. To learn more, please visit www.cleanhillpartners.com .
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211101005195/en/
Contact information
Media Relations
Hannah Arnold, The LAKPR Group
harnold@lakpr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 11:15:00 EEST | Press release
Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easier to access, navigate and manage. This will ultimately give pet parents better guidance, greater confidence and more control at every point in
Coolbrook Secures Business Finland Funding to Accelerate Electrification for the Global Steel Industry29.6.2026 11:00:00 EEST | Press release
Coolbrook, a transformational technology company dedicated to decarbonising heavy industry and industrial processes, has been awarded research and development funding by Business Finland to accelerate the decarbonisation of steel production. The grant supports Coolbrook’s participation in the FutSteel project, a core component of the Sustainable World through Steels ecosystem led by SSAB. Within the broader FutSteel project, Coolbrook’s project scope amounts to €5 million, of which €2.5 million is covered by grant funding awarded to Coolbrook. The funding will enable Coolbrook to further accelerate and develop its next-generation RotoDynamic Heater™ (RDH™) technology, specifically tailored for high-temperature steel industry applications. The project focuses on integrating RDH™ technology into critical stages of the steel production chain, including blast furnace processes, electrified reheating, hot-stove air pre-heating, hybrid-heating concepts, decarbonised Direct Reduced Iron (DRI)
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release
Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom